Dr. Sise’s complete bibliography is available here.
- Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database
- Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
- Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease
- Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
- Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease
- Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer
- Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
- Timing of invasive mechanical ventilation and death in critically ill adults with COVID-19: A multicenter cohort study
- Brief Report: Use and Side Effects of Sodium-Glucose Transporter 2 Inhibitors Among US People With HIV With Clinical Indications
- Development and Validation of a Risk Model for Predicting Contrast-Associated Acute Kidney Injury in Patients With Cancer: Evaluation in Over 46,000 CT Examinations
- Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors
- Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
- Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure
- Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function
- Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
- Reply to 'Use of convalescent plasma in the treatment of COVID-19'
- Early initiation of glecaprevir/pibrentasvir after transplantation of HCV-viremic kidneys into HCV-negative recipients is associated with normalization in the altered inflammatory milieu
- Author Correction: Therapeutic advances in COVID-19
- Authors' Reply
- Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR
